[go: up one dir, main page]

MX2023005565A - Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof. - Google Patents

Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof.

Info

Publication number
MX2023005565A
MX2023005565A MX2023005565A MX2023005565A MX2023005565A MX 2023005565 A MX2023005565 A MX 2023005565A MX 2023005565 A MX2023005565 A MX 2023005565A MX 2023005565 A MX2023005565 A MX 2023005565A MX 2023005565 A MX2023005565 A MX 2023005565A
Authority
MX
Mexico
Prior art keywords
tgf
rankl
activin
bifunctional
bone
Prior art date
Application number
MX2023005565A
Other languages
Spanish (es)
Inventor
Hq Han
Xiaolan Zhou
Original Assignee
Hq Han
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hq Han filed Critical Hq Han
Publication of MX2023005565A publication Critical patent/MX2023005565A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)

Abstract

This invention disclosure provides novel bifunctional molecules comprising at least one RANKL binding molecule and at least one Activin or TGF-β binding molecule, which are capable of sequestering RANKL and Activin or TGF-β in parallel. Also provided are pharmaceutical compositions of such bifunctional antagonist molecules and their therapeutic uses to treat various bone disorders whose pathogenesis involves the activation of both RANKL-NFKB and Î`ctivin/TGF-β-Smad2/3 signaling pathways, such as bone metastasis, bone loss in cancer, bone fragility in neuromuscular diseases, osteogenesis imperfecta, fracture, osteopenia and osteoporosis.
MX2023005565A 2020-11-11 2021-11-05 Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof. MX2023005565A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063112380P 2020-11-11 2020-11-11
US202063113922P 2020-11-15 2020-11-15
PCT/US2021/058181 WO2022103660A1 (en) 2020-11-11 2021-11-05 Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof

Publications (1)

Publication Number Publication Date
MX2023005565A true MX2023005565A (en) 2024-02-23

Family

ID=81601668

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023005565A MX2023005565A (en) 2020-11-11 2021-11-05 Bifunctional antagonists of activin/tgf-beta and rankl and uses thereof.

Country Status (7)

Country Link
EP (1) EP4243931A4 (en)
JP (1) JP2023548346A (en)
KR (1) KR20230118573A (en)
AU (1) AU2021377176A1 (en)
CA (1) CA3197104A1 (en)
MX (1) MX2023005565A (en)
WO (1) WO2022103660A1 (en)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110044991A (en) * 2008-07-02 2011-05-03 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 TNP-α antagonist multi-target binding protein
US20110305694A1 (en) * 2009-02-24 2011-12-15 Paul Andrew Hamblin Multivalent and/or multispecific rankl-binding constructs
US20120071634A1 (en) * 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
CN105431453A (en) * 2012-11-01 2016-03-23 艾伯维公司 Stable dual variable domain immunoglobulin protein formulations
US20160075772A1 (en) * 2014-09-12 2016-03-17 Regeneron Pharmaceuticals, Inc. Treatment of Fibrodysplasia Ossificans Progressiva
US10227411B2 (en) * 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
WO2018009732A1 (en) * 2016-07-08 2018-01-11 Regeneron Pharmaceuticals, Inc. Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
WO2018026742A1 (en) * 2016-08-01 2018-02-08 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
JOP20190255A1 (en) * 2017-04-28 2019-10-27 Amgen Inc Human RANKL antibody formulas, and methods for their use
CN111492066A (en) * 2017-10-20 2020-08-04 国家儿童医疗中心 Methods of using transcripts for antibody orientation and compositions derived therefrom
KR20210110818A (en) * 2018-12-05 2021-09-09 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 RANK antagonists and uses therefor

Also Published As

Publication number Publication date
AU2021377176A1 (en) 2023-06-22
WO2022103660A1 (en) 2022-05-19
JP2023548346A (en) 2023-11-16
EP4243931A4 (en) 2025-01-01
KR20230118573A (en) 2023-08-11
CA3197104A1 (en) 2022-05-19
EP4243931A1 (en) 2023-09-20

Similar Documents

Publication Publication Date Title
BR112022002599A2 (en) EXTRACELLULAR VESICLE BOUND TO MOLECULES AND USES OF IT
EA201991480A1 (en) BESPECIFIC MOLECULES RELATING TO ANTI-FNO-RELATING APOPTOSIS LIGAND RECEPTOR 2 AND ANTI-CADHERIN 17 FOR TREATMENT OF CANCER
BR112018013827A2 (en) 5'-nucleotidase modulators, ecto and use thereof
EA200702656A1 (en) COMPOSITIONS CONTAINING PEPTIDES, STIMULATING THE ERYTHROPOIETHIN RECEPTOR AND THEIR APPLICATION
EA200901166A1 (en) CONNECTIONS AND COMPOSITIONS AS GPR 119 ACTIVITY MODULATORS
NO20054769D0 (en) Substituted phenylalkanoic acids
PH12020550986A1 (en) Heterocyclylamino-substituted triazoles as modulators of rho-associated protein kinase
MX2016012716A (en) Compounds and methods for trans-membrane delivery of molecules.
MXPA05011523A (en) Substituted heteroaryls as inhibitors of protein tyrosine phosphatases.
CY1118044T1 (en) COMPOSITION PREPARATION WITH COMPETITOR AND CORTICOSTEROIDS
CY1110965T1 (en) ADDITIONAL HYPERPYROCYCLIC COMPOUNDS AND THEIR USE AS GLUTAMIC METHOD
UA107783C2 (en) Isoindoline compounds for use in treating cancer
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
CY1118966T1 (en) NEW COMPOSITIONS FOR THE PREVENTION AND / OR TREATMENT OF CENTRAL NERVOUS SYSTEMS
GT200800198A (en) COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF THE ACTIVITY OF THE CANABINOID RECEIVER OF TYPE 1.
EA201170624A1 (en) ISONICOTINAMIDE ANTAGONISTS OF OREXIN RECEPTORS
ECSP088804A (en) ANTAGONISTS OF THE AMIDA PIRIDIL OF THE TYPE T CALCIUM CHANNELS
CL2009000699A1 (en) Compounds derived from polysubstituted 6-heteroaryl-imidazo [1,2-a] pyridines; pharmaceutical composition; synthesis procedure; intermediate compounds; and its use to treat or prevent neurodegenerative, psychiatric, inflammatory diseases, brain trauma and epilepsy, osteoporosis, cancer, Parkinson's, among others.
MXPA05011524A (en) Substituted carboxylic acids.
TN2009000323A1 (en) Modulators of sclerostin binding partners for treating bone-related disorders
TW200740808A (en) Inhibiteurs de proteines kinases
TW200630327A (en) Substituted phenylalkanoic acids
EA200801343A1 (en) IMMUNOGLOBULINS DIRECTED AGAINST NOGO
MX2024000208A (en) Novel therapeutic delivery moieties and uses thereof.
EA201890198A1 (en) NEW PROTEINS SPECIFIC FOR THE LAG-3